Tenax Therapeutics, Inc. (TENX) has a negative trailing P/E of -11.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 73.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -9.01%, forward earnings yield 1.37%.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.2 | -0.01 | 3.20 | 0.00 | - |
| 2017 | -1.6 | 0.00 | 1.62 | 0.00 | - |
| 2018 | -0.3 | 0.01 | 0.15 | 0.00 | 413.82% |
| 2019 | -1.0 | 0.01 | 2.32 | 0.00 | - |
| 2020 | -1.4 | 0.00 | 2.98 | 0.00 | - |
| 2021 | -0.7 | -0.04 | 5.04 | 0.00 | - |
| 2022 | -0.3 | 0.00 | 2.19 | 0.00 | - |
| 2023 | -0.7 | 0.01 | 0.67 | 0.00 | - |
| 2024 | -5.4 | 0.06 | 1.03 | 0.00 | - |
| 2025 | -9.1 | -0.55 | 4.92 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-624.82 | $0.00 | $-43.92M | - |
| 2017 | $-10,022.30 | $0.00 | $-8.84M | - |
| 2018 | $-7,359.14 | $0.00 | $-6.81M | - |
| 2019 | $-26.60 | $0.00 | $-8.39M | - |
| 2020 | $-1,523.80 | $0.00 | $-9.85M | - |
| 2021 | $-2,524.80 | $0.00 | $-32.47M | - |
| 2022 | $-600.80 | $0.00 | $-11.05M | - |
| 2023 | $-31.04 | $0.00 | $-7.71M | - |
| 2024 | $-1.15 | $0.00 | $-17.6M | - |
| 2025 | $-1.34 | $0.00 | $-52.6M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.56 | $-4.53 – $-0.83 | $4.16M | $4.16M – $4.16M | 6 |
| 2027 | $-1.46 | $-3.44 – $-0.70 | $12.9M | $12.9M – $12.9M | 4 |
| 2028 | $-1.07 | $-1.83 – $1.57 | $46.67M | $46.67M – $46.67M | 5 |
| 2029 | $-1.02 | $-1.02 – $-1.02 | $144M | $144M – $144M | 1 |
| 2030 | $0.19 | $0.19 – $0.19 | $296.27M | $296.27M – $296.27M | 1 |
